Enzo Biochem, Inc. (NYSE:ENZ) Short Interest Down 9.3% in November

Enzo Biochem, Inc. (NYSE:ENZ) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 433,000 shares, a decrease of 9.3% from the October 31st total of 477,500 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average daily trading volume, of 86,700 shares, the short-interest ratio is currently 5.0 days.

Institutional Investors Weigh In On Enzo Biochem

Several hedge funds and other institutional investors have recently bought and sold shares of ENZ. Geode Capital Management LLC grew its stake in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after purchasing an additional 11,742 shares during the last quarter. XTX Topco Ltd grew its position in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after buying an additional 13,735 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after buying an additional 64,417 shares in the last quarter. Finally, BBR Partners LLC acquired a new stake in shares of Enzo Biochem during the 3rd quarter valued at $112,000. 36.90% of the stock is currently owned by institutional investors.

Enzo Biochem Trading Up 4.9 %

Enzo Biochem stock opened at $1.08 on Monday. Enzo Biochem has a 12-month low of $0.93 and a 12-month high of $1.50. The firm has a 50 day simple moving average of $1.11 and a 200-day simple moving average of $1.11.

Enzo Biochem Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 15th will be paid a dividend of $0.10 per share. The ex-dividend date is Friday, November 15th. This represents a $0.40 annualized dividend and a yield of 37.04%.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Enzo Biochem in a report on Sunday. They issued a “hold” rating for the company.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.